Encyclopedia of Drug
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Immunogenicity and Smoking Cessation Outcomes for a Novel Nicotine Immunotherapeutic Cheryl A
University of Connecticut OpenCommons@UConn UCHC Articles - Research University of Connecticut Health Center Research 3-2011 Immunogenicity and Smoking Cessation Outcomes for a Novel Nicotine Immunotherapeutic Cheryl A. Oncken University of Connecticut School of Medicine and Dentistry Follow this and additional works at: https://opencommons.uconn.edu/uchcres_articles Part of the Medicine and Health Sciences Commons Recommended Citation Oncken, Cheryl A., "Immunogenicity and Smoking Cessation Outcomes for a Novel Nicotine Immunotherapeutic" (2011). UCHC Articles - Research. 243. https://opencommons.uconn.edu/uchcres_articles/243 NIH Public Access Author Manuscript Clin Pharmacol Ther. Author manuscript; available in PMC 2014 July 22. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Clin Pharmacol Ther. 2011 March ; 89(3): 392–399. doi:10.1038/clpt.2010.317. Immunogenicity and Smoking Cessation Outcomes for a Novel Nicotine Immunotherapeutic Dorothy K. Hatsukami1, Douglas E. Jorenby2, David Gonzales3, Nancy A. Rigotti4, Elbert D. Glover5, Cheryl A. Oncken6, Donald P. Tashkin7, Victor I. Reus8, Roxanne C. Akhavain9, Raafat E.F. Fahim9, Paul D. Kessler9, Minoo Niknian9, Matthew W. Kalnik9, and Stephen I. Rennard10 1Dept. of Psychiatry, University of Minnesota Tobacco Use Programs, Minneapolis, MN 2Department of Medicine, University of Wisconsin, Madison, WI 3Department of Medicine, Oregon Health & Sciences University, Portland, OR 4Tobacco Research and Treatment Center, Massachusetts -
ABSTRACT Title of Dissertation
ABSTRACT Title of dissertation: THE ASSOCIATION BETWEEN ELECTRONIC CIGARETTE USE AND CIGARETTE SMOKING BEHAVIOR AMONG YOUNG ADULTS IN THE UNITED STATES Blair N. Coleman, Doctor of Philosophy, 2015 Dissertation directed by: Associate Professor Kerry M. Green Department of Behavioral and Community Health The prevalence of electronic cigarette (e-cigarette) use is rapidly increasing in adults and youth; however, little is known about the public health impact of their use. A debate over e-cigarettes has emerged in the literature; one side recognizes the potential benefit of e-cigarettes as a harm reduction tool, while others argue e-cigarette use may delay or deter smoking cessation due to dual use or increase the risk of initiation of conventional cigarettes among previous nonsmokers. Drawing on the Theory of Planned Behavior, this dissertation focused on attitudes, beliefs, and perceived social norms of e- cigarettes, as well as openness to conventional cigarette smoking among young adult users of the product. Using a mixed methods approach, this dissertation analyzed secondary data from the 2012-2013 National Adult Tobacco Survey (NATS) as well as focus group data collected in five cities across the U.S. to better understand the relationship between e- cigarette use and cigarette smoking among young adults. In Study 1, quantitative analyses found non-cigarette smoking young adults who have tried e-cigarettes were more likely to report openness to cigarette smoking in the future compared to those who have not tried e-cigarettes (AOR= 2.4; 95% CI= 1.7-3.3). In Study 2, qualitative findings suggest that young adult exclusive e-cigarette users were less interested in conventional cigarette smoking, and overwhelmingly described negative aspects to cigarette smoking that appeared to become more salient as a result of their e-cigarette use. -
Antidepressants for Smoking Cessation (Review)
Antidepressants for smoking cessation (Review) Hughes JR, Stead LF, Lancaster T This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2011, Issue 8 http://www.thecochranelibrary.com Antidepressants for smoking cessation (Review) Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 3 METHODS ...................................... 3 RESULTS....................................... 4 Figure1. ..................................... 9 Figure2. ..................................... 12 DISCUSSION ..................................... 15 AUTHORS’CONCLUSIONS . 16 ACKNOWLEDGEMENTS . 17 REFERENCES ..................................... 18 CHARACTERISTICSOFSTUDIES . 33 DATAANDANALYSES. 93 Analysis 1.1. Comparison 1 Bupropion. Abstinence at 6m or greater follow-up, Outcome 1 Bupropion versus placebo/control. Subgroups by length of follow-up. ............ 95 Analysis 1.2. Comparison 1 Bupropion. Abstinence at 6m or greater follow-up, Outcome 2 Bupropion versus placebo/control. Subgroups by clinical/recruitment setting. ................. 97 Analysis 1.3. Comparison 1 Bupropion. Abstinence at 6m or greater follow-up, Outcome 3 Bupropion versus placebo. Subgroups by level of behavioural support. .......... 100 Analysis -
Smoking Cessation with Varenicline, a Selective
ORIGINAL INVESTIGATION Smoking Cessation With Varenicline, a Selective ␣42 Nicotinic Receptor Partial Agonist Results From a 7-Week, Randomized, Placebo- and Bupropion-Controlled Trial With 1-Year Follow-up Mitchell Nides, PhD; Cheryl Oncken, MD, MPH; David Gonzales, PhD; Stephen Rennard, MD; Eric J. Watsky, MD; Rich Anziano, MS; Karen R. Reeves, MD; for the Varenicline Study Group Background: Currently available smoking cessation cline tartrate, 1.0 mg twice daily (48.0%; PϽ.001) and 1.0 therapies have limited success rates. Varenicline tar- mg once daily (37.3%; PϽ.001), than for placebo (17.1%). trate is a novel, selective nicotinic receptor partial ago- The bupropion rate was 33.3% (P=.002 vs placebo). The car- nist developed specifically for smoking cessation. This bon monoxide–confirmed continuous quit rates from week study evaluated the efficacy, tolerability, and safety of 3 4 to week 52 were significantly higher in the varenicline tar- varenicline doses for smoking cessation. Bupropion hy- trate, 1.0 mg twice daily, group compared with the placebo drochloride was included as an active control. group(14.4%vs4.9%;P=.002).Thebupropionratewas6.3% (P=.60 vs placebo). Discontinuation owing to treatment- Methods: A phase 2, multicenter, randomized, double- emergent adverse events was 15.9% for bupropion, 11.2% blind, placebo-controlled study of healthy smokers (18-65 to14.3%forvarenicline,and9.8%forplacebo.Nodose-related years old). Subjects were randomized to varenicline tar- increases occurred in adverse events for varenicline. trate, 0.3 mg once daily (n=128), 1.0 mg once daily (n=128), or 1.0 mg twice daily (n=127), for 6 weeks plus Conclusions: Varenicline tartrate demonstrated both placebo for 1 week; to 150-mg sustained-release bupro- short-term (1 mg twice daily and 1 mg once daily) and pion hydrochloride twice daily (n=128) for 7 weeks; or long-term efficacy (1 mg twice daily) vs placebo. -
Wake Forest Magazine December 2002
2001-2002 Honor Roll of Donors Wake For e st M A G A Z I N E Volume 50, Number 2 December 2002 Editor: Cherin C. Poovey, poovey @wfu.edu Associate Editor: Kerry M. King (’85), [email protected] Senior Graphic Designer: Jessica Koman, [email protected] Graphic Designer: Sonya Peterson, [email protected] Photographer: Ken Bennett, [email protected] Class Notes Editor: Janet Williamson, [email protected] Contributing Writer: David Fyten, [email protected] Development Writer: Michael Strysick, [email protected] Printing: The Lane Press, Inc. Wake Forest Magazine (USPS 664-520 ISSN 0279-3946) is published four times a year in September, December, March and June by the Office of Creative Services, Wake Forest University, 1834 Wake Forest Road, Winston-Salem, NC 27109-7205. It is sent to alumni, donors and friends of the University. Periodicals postage paid at Winston-Salem, NC 27109, and additional mailing offices. Send letters to the editor ([email protected]), classnotes ([email protected]), change of address ([email protected]) and other correspondence to the e-mail addresses listed or to Wake Forest Magazine,P.O. Box 7205, Wake Forest University, Winston-Salem, NC 27109-7205. Telephone: (336) 758-5379. You can access the Web site at http://www.wfu.edu POSTMASTER: Send address changes to Wake Forest Magazine Alumni Records, P.O. Box 7227, Winston-Salem, NC 27109-7227. Volume 50, Number 2 Copyright 2002 Wake For e st M A G A Z I N E Features 12 Their Journey by Kerry M. King (’85) What lies ahead for eight freshmen? Follow them on their journey to 2006. -
Smoking Cessation with Varenicline, a Selective 4 2 Nicotinic Receptor
ORIGINAL INVESTIGATION Smoking Cessation With Varenicline, a Selective ␣42 Nicotinic Receptor Partial Agonist Results From a 7-Week, Randomized, Placebo- and Bupropion-Controlled Trial With 1-Year Follow-up Mitchell Nides, PhD; Cheryl Oncken, MD, MPH; David Gonzales, PhD; Stephen Rennard, MD; Eric J. Watsky, MD; Rich Anziano, MS; Karen R. Reeves, MD; for the Varenicline Study Group Background: Currently available smoking cessation cline tartrate, 1.0 mg twice daily (48.0%; PϽ.001) and 1.0 therapies have limited success rates. Varenicline tar- mg once daily (37.3%; PϽ.001), than for placebo (17.1%). trate is a novel, selective nicotinic receptor partial ago- The bupropion rate was 33.3% (P=.002 vs placebo). The car- nist developed specifically for smoking cessation. This bon monoxide–confirmed continuous quit rates from week study evaluated the efficacy, tolerability, and safety of 3 4 to week 52 were significantly higher in the varenicline tar- varenicline doses for smoking cessation. Bupropion hy- trate, 1.0 mg twice daily, group compared with the placebo drochloride was included as an active control. group(14.4%vs4.9%;P=.002).Thebupropionratewas6.3% (P=.60 vs placebo). Discontinuation owing to treatment- Methods: A phase 2, multicenter, randomized, double- emergent adverse events was 15.9% for bupropion, 11.2% blind, placebo-controlled study of healthy smokers (18-65 to14.3%forvarenicline,and9.8%forplacebo.Nodose-related years old). Subjects were randomized to varenicline tar- increases occurred in adverse events for varenicline. trate, 0.3 mg once daily (n=128), 1.0 mg once daily (n=128), or 1.0 mg twice daily (n=127), for 6 weeks plus Conclusions: Varenicline tartrate demonstrated both placebo for 1 week; to 150-mg sustained-release bupro- short-term (1 mg twice daily and 1 mg once daily) and pion hydrochloride twice daily (n=128) for 7 weeks; or long-term efficacy (1 mg twice daily) vs placebo.